Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/149365
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorTejeda, Gonzalo S.-
dc.contributor.authorDíaz-Guerra, Margarita-
dc.date.accessioned2017-05-06T05:36:28Z-
dc.date.available2017-05-06T05:36:28Z-
dc.date.issued2017-01-28-
dc.identifierdoi: 10.3390/ijms18020268-
dc.identifier.citationInternational Journal of Molecular Sciences 18(2): 268 (2017)-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/10261/149365-
dc.descriptionThis article belongs to the Special Issue Brain-Derived Neurotrophic Factor.-
dc.description.abstractEnhancement of brain-derived neurotrophic factor (BDNF) signalling has great potential in therapy for neurological and psychiatric disorders. This neurotrophin not only attenuates cell death but also promotes neuronal plasticity and function. However, an important challenge to this approach is the persistence of aberrant neurotrophic signalling due to a defective function of the BDNF high-affinity receptor, tropomyosin-related kinase B (TrkB), or downstream effectors. Such changes have been already described in several disorders, but their importance as pathological mechanisms has been frequently underestimated. This review highlights the relevance of an integrative characterization of aberrant BDNF/TrkB pathways for the rational design of therapies that by combining BDNF and TrkB targets could efficiently promote neurotrophic signalling.-
dc.description.sponsorshipWe acknowledge funding from Ministerio de Economía y Competitividad (BFU2013-43808-R) and Fundación Mutua Madrileña (reference No. 201322001). The cost of this publication has been paid in part by FEDER funds.-
dc.description.sponsorshipWe acknowledge support by the CSIC Open Access Publication Initiative through its Unit of Information Resources for Research (URICI).-
dc.publisherMultidisciplinary Digital Publishing Institute-
dc.relationinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BFU2013-43808-R-
dc.relation.isversionofPublisher's version-
dc.titleIntegral characterization of defective BDNF/TrkB signalling in neurological and psychiatric disorders leads the way to new therapies-
dc.identifier.doi10.3390/ijms18020268-
dc.relation.publisherversionhttps://doi.org/10.3390/ijms18020268-
dc.date.updated2017-05-06T05:36:28Z-
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0/-
dc.contributor.funderFundación Mutua Madrileña-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderEuropean Commission-
dc.contributor.funderConsejo Superior de Investigaciones Científicas (España)-
dc.identifier.funderhttp://dx.doi.org/10.13039/100008061es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003339es_ES
dc.identifier.pmid28134845-
item.grantfulltextopen-
item.fulltextWith Fulltext-
Aparece en las colecciones: (IIBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
ijms-18-00268-v2.pdf1,75 MBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

PubMed Central
Citations

46
checked on 24-ene-2024

SCOPUSTM   
Citations

51
checked on 30-nov-2021

WEB OF SCIENCETM
Citations

52
checked on 01-dic-2021

Page view(s)

199
checked on 28-mar-2024

Download(s)

280
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric



Este item está licenciado bajo una Licencia Creative Commons Creative Commons